Abstract
The authors determined the prevalence of hyperprolactinemia in impotent men in a community setting and assessed the cost of case detection with routine estimation of serum prolactin. They recruited 299 consecutive patients with impotence and determined the hormonal levels (prolactin, luteinizing hormone, follicle-stimulating hormone, and testosterone). Pituitary gland imaging was done when the prolactin level was elevated. Simultaneous prolactin and testosterone levels were available for 212 patients. Three patients (1.4% ) had elevated prolactin levels but none had pituitary tumor. Two of these had low testosterone levels. Overall, 51 patients (24.1%) had low testosterone levels. Cost of selective prolactin estimation in patients with low testosterone levels resulted in a net saving of $2,574 per case detected. The authors conclude that the prevalence of hyperprolactinemia in impotence is low. Routine measurement of prolactin levels in impotence is not indicated. Selective determination in patients with low testosterone reduces the cost of diagnostic evaluation.
This is a preview of subscription content, log in via an institution to check access.
References
Krane R. Sexual function and dysfunction. In: Campbell’s Urology, 5th edition. Philadelphia: W. B. Saunders, 1986;717.
Whitehead ED, Klyde BJ, Zussman S, Salkin P. Diagnostic evaluation of impotence. Postgrad Med. 1990;8:123–36.
Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med. 1989;321:1648–59.
Korenman SG. Sexual dysfunction. In: Williams’ Textbook of Endocrinology, 8th edition. Philadelphia: W. B. Saunders, 1992;1039.
Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin secreting tumors and hypogonadism in 22 men. N Engl J Med. 1978;299:847–52.
Franks S, Jacobs HS, Martin N, Nabarro JDN. Hyperprolactinaemia and impotence. Clin Endocrinol. 1978;8:277–87.
Miller JB, Howards SS, McLeod RM. Serum prolactin in organic and psychogenic impotence. J Urol. 1980;123:862–4.
Modebo O. Serum prolactin concentration in impotence in African males. Andrologia. 1989;21(1):42–7.
Hargrave TB, Kyle KF, Kelley AM, England P. Prolactin and gonadotrophins in 208 men presenting with infertility. Br J Urol. 1977;49:747–50.
Buvat J, Lemaire A, Buvat-Herbaut M, Fourlinnie JC, Racadot A, Fossati P. Hyperprolactinemia and sexual function in men. Horm Res. 1985;22:196–203.
Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence. Why, when, and how to investigate. J Urol. 1989;142:992–4.
Maatman TJ, Montague DK. Routine endocrine screening in impotence. Urology. 1986;27:499–502.
Nickel JC, Morales A, Condra M, Fenemore J, Surridge DH. Endocrine dysfunction in impotence. Incidence significance and cost effective screening. J Urol. 1984;132:40–3.
Hursch CJ, Karacan I, Williams RL. Some characteristics of penile tumescence in early middle-aged males. Compr Psychiatry. 1972;13:539–48.
Wein AJ, Fishkin R, Carpiniello VL, Malloy TR. Expansion without significant rigidity during nocturnal penile tumescence testing. A potential source of misinterpretation. J Urol. 1981;126:343–4.
Farlow WM. Prevalence of impotence in the United States. Med Aspect Hum Sexuality. 1985;19:13–6.
Katz E, Adashi EY. Hyperprolactinemic disorders. Clin Obstet Gynecol. 1990;33:622–39.
Foster RS, Mulcahy JJ, Callaghan JT, Crabtree R, Brashear D. Role of serum prolactin determination in evaluation of impotent patient. Urology. 1990;36:499–501.
Johnson AR III, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol. 1992;147:1542–4.
Author information
Authors and Affiliations
Additional information
Received from the Medical College of Ohio, Toledo Ohio.
Supported in part by a grant from Palisades Pharmaceutical, Tenafly, NJ.
Rights and permissions
About this article
Cite this article
Akpunonu, B.E., Mutgi, A.B., Federman, D.J. et al. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med 9, 336–338 (1994). https://doi.org/10.1007/BF02599183
Issue Date:
DOI: https://doi.org/10.1007/BF02599183